The blood coagulation system is activated regularly in severe forms of shock, polytrauma, and sepsis. Arising thrombin cleaves the fibrinopeptides A and B from fibrinogen, and it generates monomers of fibrin, which are initially kept in solution by the remaining excess fibrinogen. The effects of soluble fibrin (fibrin monomer/oligomer-fibrinogen complexes) and fibrinopeptides A and B were investigated in blood-free perfused, isolated rabbit lungs. Urea Tris buffer-dissolved fibrin monomers were injected into the pulmonary artery in the presence of circulating excess fibrinogen. In doses above 5 mg, the monomers consistently provoked a sharp rise in pulmonary artery pressure, which was followed by an elevated pressure plateau. Changing to fresh perfusate devoid of soluble fibrin did not restore the pressure to baseline, and a second administration of the soluble fibrin caused a pressor response larger than the first. Only a modest increase in lung weight (< 2 g) was observed, and lung inflation pressure was not altered. The pressor responses were accompanied by a rapid release of thromboxane A 2 and a more delayed release of prostaglandin I, into the perfusion fluid. A significant correlation between the height of the fibrin-induced pressure rise and the amount of thromboxane release was noted. Inhibition of cyclooxygenase (indomethacin) suppressed the generation of both prostanoids, whereas inhibition of thromboxane synthetase (OKY-046 and imidazole) selectively blocked the liberation of thromboxane. All three inhibitors caused an immediate decline in pulmonary artery pressure, which had been previously elevated due to administration of soluble fibrin, and markedly reduced the pressor response evoked by a subsequent fibrin application in the same lung. Pulmonary artery injection of the fibrinopeptides A and B, up to a dose of 1 mg each, did not affect the pulmonary circulation. We conclude that soluble fibrin monomer/oligomer-fibrinogen complexes, in amounts corresponding to 1-3% of the circulating fibrinogen, cause an acute pulmonary hypertension in rabbit lungs that may be relevant under conditions of an activated coagulation system. A major component of the vasoconstrictor response appears to be mediated by pulmonary thromboxane generation. (Circulation Research 1988;62:651-659) T he blood coagulation system is activated regularly in severe forms of shock, polytrauma, and sepsis.'" 4 The inherent events of increased turnover of clotting factors, intravascular fibrin formation, and pulmonary deposition of fibrin(ogen) products are considered as causative factors of the acute respiratory distress syndrome of the adult, characterized by pulmonary hypertension and vascular leakage. 5 " 12 These alterations of lung hemodynamics and fluid balance were mimicked in different animal models by intravenous infusion of sublethal doses of thrombin. 13 " 18 Thrombin generates self-aggregating monomers of fibrin by proteotytic cleavage of the fibrinopeptides A and B from fibrinogen, and micro-embolism of the pulmonary vasculature with aggregated fibrin and fibrin-rich particles has been reported as an important pathophysiological event.' 9 " 21 The microvascular effects evoked by embolization of the pulmonary vessels with small particles appear to be partly mediated by activation and adherence of circulating granulocytes. 13 -2022 Besides generation of insoluble fibrin strands, there are soluble compounds arising during the terminal sequence of the coagulation cascade, which might in themselves have vasoactive potency. In addition to thrombin and the fibrinopeptides A and B, so-called soluble fibrin can be demonstrated in vitro and can be recovered from the circulation in vivo. In the intermediary stages of coagulation, the arising fibrin monomers interact with unconverted fibrinogen. This interaction impedes the polymerization to insoluble fibrin and enables remarkable amounts to be transported as soluble fibrin monomer/oligomer-fibrinogen complexes. 23 " 36 Under pathophysiological conditions commonly associated with a disseminated intravascular activation of the coagulation system, plasma soluble fibrin was found to represent from 2 to >10% of the total circulating fibrinogen. 37 ' 41 Moreover, there is considerable generation of soluble fibrin during the production and storage of different blood components, including CPD-blood, SAGM-suspended red cells, and cryoprecipitates of
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Materials and Methods

Model of Isolated Lungs
The model has been previously described. 50 " 52 Briefly, rabbits of either sex (weighing 2.3-2.8 kg) were deeply anesthetized with sodium pentobarbital 60-90 mg/kg body wt and were anticoagulated with heparin 1,000 units/kg body wt. The isolated lungs, suspended freely from a force transducer in a chamber warmed to 38° C, were ventilated with 4% CO 2 -17% O 2 -79% N 2 (frequency, 45 strokes/min; tidal volume, 30 ml) and were perfused with Krebs-Henseleit buffer with bovine albumin (4% wt/vol) or hydroxyethylamylopectin (200,000 mol wt; 4% wt/vol) as oncotic substances. A recirculating system (circulating volume, 125 ml) with a pulsatile flow of 200 ml/min was used. In the case of fibrin monomer injection, bovine fibrinogen (250 mg% wt/vol) was admixed to the albumin buffer before recirculation to allow the generation of soluble fibrin monomer/oligomer-fibrinogen complexes. The left atrial pressure was set at zero (0 referenced at the hilum), except for five experiments with venous pressure challenge. By the alternate use of two different perfusion systems, it was possible to perform repetitive perfusion phases in the same isolated lung, each with fresh perfusion fluid. In the standard protocol ( Figures 1-3 and 5), each perfusion phase lasted 10 minutes. The physical variables, perfusion pressure, ventilation pressure, and weight of the isolated lung, were registered continuously by pressure transducers and a force transducer. The reproducibil ity of these physical measurements showed a standard deviation of < 3 % . Only those lungs were selected that, after a steady-state period of at least 45 minutes with numerous changes of perfusion fluid, were completely blanched and showed no spontaneous edema formation or changes of ventilation and perfusion pressure. Light microscopic examination of these lungs revealed virtually no adherence of erythrocytes, platelets, and leukocytes to the vascular wall, and no evidence of interstitial edema or alveolar flooding was noted.
Fibrin monomers, dissolved in <500 p.1 urea (3 M) Tris (50 mM) buffer, or the fibrinopeptides A and B, dissolved in < 500 (j.1 saline, were injected directly into the pulmonary artery (injection time 10 seconds; indicated by arrows in Figures 1,2 ,4, and 5). Inhibitors were added to the perfusion fluid at the stated final concentrations before recirculation. Appropriate doses of the different inhibitors were determined by use of dose-response curves obtained from previous investigations: 1 ^M indomethacin (cyclooxygenase inhibitor) in hydroxyethylamylopectin buffer" and 35 p,M indomethacin in albumin buffer due to the albumin binding, 50 -52 0.88 mM imidazole, and 2 JJLM OKY-046 (thromboxane synthetase inhibitors). 51 
Preparation of Fibrin Monomer
Des-AB fibrin monomer was generated by clotting bovine fibrinogen dissolved in saline with excess insolubilized bovine thrombin (coupled to agarose, 100-200 mesh). 53 The arising clot was removed, washed several times with saline, dried with filter cloth, and dissolved in urea Tris buffer 23 with subsequent spinning at 5,000g for 10 minutes to remove all agarose-coupled thrombin. The concentration of fibrin monomer was determined photometrically at 280 nm. 54 Application of 10 mg fibrin monomer (in <500 p,l urea Tris buffer) to 125 ml albumin buffer in the presence of excess fibrinogen (250 mg % wt/vol) allows the formation of soluble fibrin manomer/oligomer-fibrinogen complexes. 23 -25 -26 -28 -MJ3 " 35 This was checked visually by ensuring the absence of aggregated (polymerized) fibrin, at least within the first 2 minutes, after injection of the urea Tris-dissolved fibrin monomers into noncirculating buffer fluid. 27 In contrast, when 10 mg urea Tris-dissolved fibrin monomers were injected into hydroxyethylamylopectin buffer in the absence of fibrinogen, immediate fibrin polymerization could be visualized. The fibrin monomers dissolved in the urea Tris vehicle and the nonpoh/merized fibrin arising after admixture of the monomers to the fibrinogen-containing albumin buffer are referred to as "soluble fibrin" in this study. TXA 2 and prostaglandin (PG) I 2 were assayed serologicalry in the buffer fluids as their stable hydrolysis products TXB 2 and 6-keto-PGF, a . Each assay mixture contained a 0.1-ml sample or 5-500 pg of an authentic standard, 0.1 ml antiserum (cross-reactivity with other prostaglandins, each <0.05%), tritiumlabeled TXB 2 or tracer 6-keto-PGF lQ , and phosphategelatin buffer in a total volume of 0.5 ml. Assay mixtures were incubated overnight at 4° C for 16 hours. Antibody-antigen complexes were separated from free antigen by adding charcoal suspension. Tubes were centrifuged for 10 minutes at l,OOQg and decanted into liquid scintillation vials. The limit of detection was 5 pg for TXB 2 and 10 pg for 6-keto-PGF la and 50% binding occurred at 50 pg for TXB 2 and 170 pg for 6-keto-PGF la . This assay did not detect background levels of TXB 2 or 6-keto-PGF la in the albumin buffer, whether or not it contained fibrinogen, before perfusion through the lungs. To exclude unspecific effects that might originate from the use of the charcoal separation 
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National Center Subscriptions 7320 Greenville Avenue DALLAS, TX 75231-9986 technique, 10 probes with different amounts of TXB 2 and 6-keto-PGF la were assayed in parallel with the described technique and with a double antibody method, using a goat anti-rabbit 7-globulin as precipitating antiserum." Differences between the two techniques never exceeded 10%. Lactate dehydrogenase (LDH) was measured photometrically, and potassium was measured by flame photometry. For histological evaluation, the lungs were immersed in 10% formalin with simultaneous application of formalin to the bronchial tree with a hydrostatic pressure of 15 cm H 2 O. They were stained with hematoxylin eosin.
Chemicals
OKY-046 was kindly supplied by Ono Pharmaceutical, Osaka, Japan. Indomethacin was obtained from Merck Sharp & Dohme AG, Munich, Federal Republic of Germany. Bovine albumin (92% purity, reduced in free fatty acids <5 ng/g) was purchased from Paesel, Frankfurt, Federal Republic of Germany, and hydroxyethylamylopectine from Fresenius Bad Homburg, Federal Republic of Germany. Bovine fibrinogen (95% purity) was supplied by Behring, Marburg, Federal Republic of Germany. Bovine thrombin was obtained from Hoffman LaRoche, Basel, Switzerland, and the human fibrinopeptides A and B from Serva, Heidelberg, Federal Republic of Germany. Rabbit anti-6-keto-PGF la and anti-TXB2 were purchased from Paesel. (3-H)-6keto-PGF la and (3-H)-TXB 2 were supplied by New England Nuclear, Dreieich, Federal Republic of Germany, and the unlabeled standards by Sigma, Munich, Federal Republic of Germany. All other biochemicals were obtained from Merck, Darmstadt, Federal Republic of Germany, and were used in p.a. quality.
Statistics
All data are given as mean±SEM. Analysis of variance followed by multiple comparisons and simple regression were performed.
Results
Administration of a fibrinogen-containing albumin buffer or injection of urea Tris vehicle did not alter pulmonary artery pressure. However, the administra-tion of 5-10 mg soluble fibrin in the presence of fibrinogen caused a complex pressor response composed of, in sequence, a rapid pressure increase, a small fall, a slower pressure rise, and a slow fall (Figure 1) . In 17 lungs, the administration of 10 mg soluble fibrin evoked a maximum pressure rise of 18.85 mm Hg (Table 1 ). Changing to a fresh perfusate that did not contain soluble fibrin did not restore the pressure to baseline, and a second administration of the soluble fibrin caused a pressure response larger than the first (Figure 1 and Table 1 ). Although soluble fibrin administration did not alter lung inflation pressure, we considered whether lung fluid accumulation might have caused the pressor response. In eight lungs, two sequential administrations of soluble fibrin increased lung weight by 0.78 ±0.33 g (Figure 1 ). In contrast, elevation of left atrial pressure to 20 cm H 2 O for 30 minutes in five control lungs caused a weight gain of 4.5 ± 0 . 9 g, but pulmonary arterial pressure did not increase. Thus, fluid accumulation did not seem a likely cause of the pressor response to the soluble fibrin.
The fibrin-induced pressor responses were accompanied by a rapid and sustained release into the recirculating perfusate of TXB 2 and a slower release of 6-keto-PGF la (Figure 2 and Table 2 ). The magnitude of the pressor response was significantly correlated with the level of thromboxane (Figure 3) but not with the level of 6-keto-PGF la . In the presence of the cyclooxygenase inhibitor indomethacin, the release of both thromboxane and 6-keto-PGF la was completely suppressed ( Table 2 ). The thromboxane synthetase inhibitors imidazole and OKY-046, however, blocked the thromboxane release without affecting the liberation of 6-keto-PGF la . After a fibrin-induced pressor response, changing to a fresh perfusate containing one of these inhibitors, but no soluble fibrin, caused a rapid decline in perfusion pressure to, or below, baseline values ( Figure 4) . When in the presence of one of these inhibitors, administration of the soluble fibrin was repeated the pressor response was significantly blunted ( Figure 4 and Table 1 ). In the concentrations used, indomethacin was more effective than OKY-046, which was more effective than imidazole. In four lungs, 10 mM e-amino caproic acid, a noncompetitive piasmin inhibitor, 3 * did not inhibit the response to soluble fibrin. The administration of soluble fibrin did not increase the concentrations of potassium or LDH above the baseline levels. The histologic examination of three lungs that had been formalin fixed at the height of the pressor response to 20 mg soluble fibrin showed but few fibers of aggregated fibrin.
Administration of 10 mg urea Tris-dissolved fibrin monomers to four lungs perfused with hydroxyethylamylopectin buffer in the absence of fibrinogen evoked only a very slight pressure peak of 3.2 ± 0 . 7 mm Hg. Even repetitive application of fibrin (a total of 65 mg) in the absence of circulating fibrinogen caused just a modest cumulative elevation of the pulmonary artery pressure ( Figure 5 ). Administration of 1 mg each of the fibrinopeptides A and B in three lungs provoked no pressor response at all.
Discussion
In blood-free perfused rabbit lungs, administration of fibrin monomers induced acute pulmonary hypertension. There are several lines of evidence strongly suggesting that this pressor response is caused by fibrin-induced vasoconstriction rather than by mechanical blockage of the vascular bed due to polymerized fibrin particles. First, there was excess fibrinogen present in the recirculating perfusion fluid, enabling the immediate generation of soluble fibrin monomer/oligomer-fibrinogen complexes. 23 -25 " 3133 - 34 -36 This was checked in vitro by ensuring the absence of aggregated (polymerized) fibrin after admixture of urea Tris-dissolved fibrin monomers to a fibrinogen-containing albumin buffer. Once formed, fibrin monomer/oligomer-fibrinogen complexes are known to remain soluble for hours in the circulation of rabbits and humans. 2 * 47 - 49 Second, in the absence of circulating fibrinogen and albumin, that is, in the experiments with hydroxyeth-ylamylopectin buffer fluid, immediate polymerization of the fibrin monomers to insoluble fibrin strands occurred. Therefore, mechanical blockage of the vascular bed must be assumed in these special experiments. However, even the application of a total of 65 mg fibrin within 60 minutes under these conditions provoked only a very modest increase in pulmonary vascular resistance ( Figure 5 ). Thus, the severalfold stronger pressor responses to only 10 mg soluble fibrin (presence of recirculating fibrinogen) must be ascribed to different effects. Third, the elevated pulmonary artery pressure after administration of 10 mg soluble fibrin rapidly declined to baseline levels upon subsequent application of three structurally unrelated inhibitors of arachidonic acid metabolism (indomethacin, imidazole, and OKY-046). In the absence of stimulusmediated vasoconstriction, these inhibitors provoke at most a very slight ( < 2 mm Hg) decrease of the pulmonary artery pressure. Moreover, all three inhibitors markedly reduced the pressor response evoked by a subsequent (second) fibrin application. These features are not compatible with pure mechanical vascular occlusion as a responsible factor for the noted pulmonary hypertension but can only be explained by an interference of these agents with soluble fibrin-induced vasoconstriction. Finally, the histological evaluation of lungs fixed at the height of the pressor response showed but few fibers of aggregated fibrin. Compared with the histological evaluation of lungs that were microembolized with inert particles of aggregated albumin," this is clearly insufficient to account for the marked fibrininduced pressure rise in terms of mechanical obstruction of the vascular bed. Collectively, these findings do not completely exclude the possibility that mechanical blockage of lung vessels may contribute, to a small extent, to the fibrin-induced hypertension. The pre- dominant part of the pressor response must, however, be ascribed to pulmonary vasoconstriction elicited by soluble fibrin monomer/oligomer-fibrinogen complexes. Most probably, this vasoconstrictor response was evoked by the soluble fibrin itself, and not by fibrin degradation products. There was no circulating plasminogen that could be cleaved by urokinase-like or tissue-type plasminogen activators, and e-amino caproic acid, a noncompetitive potent plasmin inhibitor, 5 * was found to be ineffective. Moreover, the instantaneous onset of the pressor response after application of the soluble fibrin argues against a preceding sequence of proteorytic cleavage. Although in the present study, bovine fibrin monomer was used throughout, parallel experiments with application of urea Tris-dissolved bovine and rabbit fibrin monomers in intact rabbits showed no difference with respect to their potencies in raising pulmonary artery pressure. 58 The fibrin-induced vasoconstriction was accompanied by a rapid and continuous release of thromboxane into the recirculating buffer fluid, significantly correlating with the degree of the pressure rise. In the presence of a cyclooxygenase inhibitor and of two structurally unrelated thromboxane synthetase inhibitors (OKY-046 and imidazole), the fibrin-induced pulmonary hypertension was significantly suppressed. The effects of OKY-046 and imidazole were found to be selective. The thromboxane generation was nearby completely blocked, whereas the release of PGI 2 was not diminished. This is in accordance with studies in tracheal strips, alveolar macrophages, and different blood cells, which characterize these agents as specific The table gives the levels of TXB 2 and 6-keto-PGF la in the recirculating perfusion fluid 1 , 3 , 5 , and 8 minutes after application of 10 mg soluble fibrin (absolute data, mean±SEM). In control phases, in which only 250 mg% fibrinogen and urea Tris buffer (vehicle for fibrin monomer) were applied, the TXB 2 and the 6-keto-PGF| a levels ranged below 100 and 200 pg/ml, respectively, at each time after onset of perfusion (/t = 4, data not given in the table).
•The Control group includes the levels obtained during the first fibrin application in six separate isolated lungs. tThe Indomethacin and IMI/OKY-046 groups give the values during a second fibrin application in the presence of indomethacin (n = 6), imidazole (n = 3), or OKY-046 (n = 3). The values obtained in the presence of both thromboxane synthetase inhibitors are given together.
tAfter the fibrin application in the presence of imidazole, there was one TXB 2 value after 3 minutes (62 pg/ml) and two values after 5 minutes (52 pg/ml and 69 pg/ml) that exceeded the detection limit of 50 pg/ml. All other values ranged below 50 pg/ml. FIGURE 3 . Correlation between the pulmonary artery pressor (PAP) responses (A/? II given, see Figure 1 ) and the maximum levels of TXB 2 released into the perfusate after application of 10 mg soluble fibrin in six different isolated lungs. The corresponding correlation coefficient for the total height of the fibrin-induced pressor responses instead of A/7 // was r = 0.90.
inhibitors of thromboxane synthetase. 5 '^6 2 Thus, even if unspecific effects of indomethacin, such as inhibition of phospholipase in higher concentrations, are considered, the inhibitory potencies of these three structurally unrelated agents collectively indicate a major role of thromboxane in the vasoconstrictor response to soluble fibrin. Moreover, from a previous study, 51 it is known that the stable TXA 2 -mimicking substance U46619 provokes an acute pressure rise in the isolated lung model when applied in the same range of concentration in which TXB 2 is detected in the perfusion fluid after administration of soluble fibrin, 51 thus supporting a significant role of the detected thromboxane. Its vasoconstrictive potency apparently surpasses the vasodilatory effect of PGI 2 , which was released more gradually than thromboxane after soluble fibrin application. This is in accordance with the pattern of prostanoid generation induced by various other stimuli that exert thromboxane-mediated pulmonary vasoconstriction accompanied by PGI 2 generation, such as staphylococcal a-toxin, 51 the calcium ionophore A23187, 63 and granulocyte-derived hydrogen peroxide. 64 Since the soluble fibrin-induced pressure rise was not completely blocked by cyclooxygenase inhibition, noncyclooxygenase metabolites of arachidonic acid with vasoactive potency may additionally be involved; these agents were, however, not addressed in the present study.
The intravenous route of application and the marked PGI 2 generation suggest a major role of endothelial cells in the pulmonary response to soluble fibrin. The cellular source of thromboxane in blood-and plasmafree perfused lungs has, however, not yet been established. Alveolar, interstitial, or even resident intravascular macrophages may be of major importance in this connection. 65 and platelets 70 has been demonstrated; however, no information is available concerning the interaction of soluble fibrin with lung vascular or perivascular cells. The absence of LDH-and potassium-release after fibrin administration indicates the absence of overt cellular damage, which is found, for example, after application of Pseudomonas aeruginosa cytotoxin in the isolated lung model. 71 -72 This is in accordance with studies in endothelial cell monolayers, in which morphological changes and disorganization were not noted during a period of 2 hours after application of fibrin. 7374 In contrast to soluble fibrin, no vasoactive potency in blood-free perfused lungs could be demonstrated for the fibrinopeptides A and B, even when used in very high concentrations. This observation conflicts with a previous study in which a significant pulmonary hypertension was noted after the application of far smaller doses of bovine fibrinopeptides in intact rabbits, dogs, and lambs. 75 An explanation for this discrepancy may be the absence of circulating inflammatory cells in the present study, because fibrinopeptide B, for example, is known to possess marked chemotactic activity for neutrophils and thus may exert effects in intact animals through stimulation of these cells. 76 As already mentioned, numerous studies have documented the fact that fibrin may exist in a soluble form in the circulation, generally complexed with fibrinogen. Under pathophysiological circumstances, plasma soluble fibrin was measured to represent from 2 to > 10% of the total circulating fibrinogen, and the percentage of soluble fibrin in different stored blood components may surpass 5% of the included fibrinogen. The amounts of soluble fibrin applied in the present study correspond to approximately 1-3% of the circulating fibrinogen of rabbits. Soluble fibrin must thus be considered a pulmonary vasoconstrictor agent in situations of disseminated intravascular coagulation and multitransfusion and may be relevant for the understanding of lung injury encountered under these circumstances. Soluble fibrin exerted its effect in blood-free perfused lungs (i.e., without enlisting the aid of circulating inflammatory cells such as granulocytes); however, it is also effective in the same dose range in intact rabbits. 58 Soluble fibrin monomer/oligomer-fibrinogen complexes thus enlarge the list of vasoactive potencies ascribed to coagulation products. 77 
